Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Documenti analoghi

• Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy
  di: Konig, Maximilian F, et al.
  Pubblicazione: (2021)
• Hydroxychloroquine use in a community-based cohort of patients with systemic lupus erythematosus
  di: Schmajuk, Gabriela, et al.
  Pubblicazione: (2010)
• Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know
  di: Yazdany, Jinoos, et al.
  Pubblicazione: (2020)
• Higher Hydroxychloroquine Blood Levels Are Associated with Reduced Thrombosis Risk in Systemic Lupus Erythematosus
  di: Petri, Michelle, et al.
  Pubblicazione: (2021)
• Health-related quality of life measurement in systemic lupus erythematosus: The LupusQoL, SLEQoL, and L-QoL
  di: Yazdany, Jinoos
  Pubblicazione: (2011)